Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles
Muñoz-Wolf, Natalia and Ward, Ross W. and Hearnden, Claire H. and Sharp, Fiona A. and Geoghegan, Joan and O'Grady, Katie and McEntee, Craig P. and Shanahan, Katharine A. and Guy, Coralie and Bowie, Andrew G. and Campbell, Matthew and Roces, Carla B. and Anderluzzi, Giulia and Webb, Cameron and Perrie, Yvonne and Creagh, Emma and Lavelle, Ed C. (2023) Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles. Cell Reports Medicine, 4 (1). 100899. (https://doi.org/10.1016/j.xcrm.2022.100899)
Preview |
Text.
Filename: Mu_oz_Wolf_etal_CRM_2023_Non_canonical_inflammasome_activation_mediates_the_adjuvanticity_of_nanoparticles.pdf
Final Published Version License: Download (3MB)| Preview |
Abstract
The non-canonical inflammasome sensor caspase-11 and gasdermin D (GSDMD) drive inflammation and pyroptosis, a type of immunogenic cell death that favors cell-mediated immunity (CMI) in cancer, infection, and autoimmunity. Here we show that caspase-11 and GSDMD are required for CD8+ and Th1 responses induced by nanoparticulate vaccine adjuvants. We demonstrate that nanoparticle-induced reactive oxygen species (ROS) are size dependent and essential for CMI, and we identify 50- to 60-nm nanoparticles as optimal inducers of ROS, GSDMD activation, and Th1 and CD8+ responses. We reveal a division of labor for IL-1 and IL-18, where IL-1 supports Th1 and IL-18 promotes CD8+ responses. Exploiting size as a key attribute, we demonstrate that biodegradable poly-lactic co-glycolic acid nanoparticles are potent CMI-inducing adjuvants. Our work implicates ROS and the non-canonical inflammasome in the mode of action of polymeric nanoparticulate adjuvants and establishes adjuvant size as a key design principle for vaccines against cancer and intracellular pathogens.
-
-
Item type: Article ID code: 84023 Dates: DateEvent17 January 2023Published19 December 2022AcceptedSubjects: Science > Microbiology
Technology > Engineering (General). Civil engineering (General) > BioengineeringDepartment: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Depositing user: Pure Administrator Date deposited: 06 Feb 2023 15:30 Last modified: 11 Nov 2024 13:47 URI: https://strathprints.strath.ac.uk/id/eprint/84023